Literature DB >> 27517125

Copper Binding and Subsequent Aggregation of α-Synuclein Are Modulated by N-Terminal Acetylation and Ablated by the H50Q Missense Mutation.

Rebecca J Mason1, Aimee R Paskins1, Caroline F Dalton1, David P Smith1.   

Abstract

The Parkinson's disease-associated protein α-synuclein exhibits significant conformational heterogeneity. Bacterially expressed α-synuclein is known to bind to copper, resulting in the formation of aggregation-prone compact conformations. However, in vivo, α-synuclein undergoes acetylation at its N-terminus. Here the effect of this modification and the pathological H50Q mutation on copper binding and subsequent conformational transitions were investigated by electrospray ionization-ion mobility spectrometry-mass spectrometry. We demonstrate that acetylation perturbs the ability of α-synuclein to bind copper and that the H50Q missense mutation in the presence of N-terminal acetylation prevents copper binding. These modifications and mutations prevent the formation of the most compact conformations and inhibit copper-induced aggregation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27517125     DOI: 10.1021/acs.biochem.6b00708

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Pulsed Hydrogen-Deuterium Exchange Illuminates the Aggregation Kinetics of α-Synuclein, the Causative Agent for Parkinson's Disease.

Authors:  Eva Illes-Toth; Don L Rempel; Michael L Gross
Journal:  ACS Chem Neurosci       Date:  2018-04-11       Impact factor: 4.418

Review 2.  A multi-faceted genotoxic network of alpha-synuclein in the nucleus and mitochondria of dopaminergic neurons in Parkinson's disease: Emerging concepts and challenges.

Authors:  Velmarini Vasquez; Joy Mitra; Haibo Wang; Pavana M Hegde; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2019-12-18       Impact factor: 11.685

3.  Cu and Zn coordination to amyloid peptides: From fascinating chemistry to debated pathological relevance.

Authors:  Elena Atrián-Blasco; Paulina Gonzalez; Alice Santoro; Bruno Alies; Peter Faller; Christelle Hureau
Journal:  Coord Chem Rev       Date:  2018-09-15       Impact factor: 22.315

4.  Acetylation Rather than H50Q Mutation Impacts the Kinetics of Cu(II) Binding to α-Synuclein.

Authors:  Xiangyu Teng; Alena Sheveleva; Floriana Tuna; Keith R Willison; Liming Ying
Journal:  Chemphyschem       Date:  2021-10-14       Impact factor: 3.520

5.  NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma.

Authors:  Leire Neri; Marta Lasa; Alberto Elosegui-Artola; Delia D'Avola; Beatriz Carte; Cristina Gazquez; Sara Alve; Pere Roca-Cusachs; Mercedes Iñarrairaegui; Jose Herrero; Jesús Prieto; Bruno Sangro; Rafael Aldabe
Journal:  Oncotarget       Date:  2017-06-20

6.  Copper(II) and the pathological H50Q α-synuclein mutant: Environment meets genetics.

Authors:  Anna Villar-Piqué; Giulia Rossetti; Salvador Ventura; Paolo Carloni; Claudio O Fernández; Tiago Fleming Outeiro
Journal:  Commun Integr Biol       Date:  2017-02-06

Review 7.  Copper Ions and Parkinson's Disease: Why Is Homeostasis So Relevant?

Authors:  Marco Bisaglia; Luigi Bubacco
Journal:  Biomolecules       Date:  2020-01-29

8.  Molecular basis for N-terminal alpha-synuclein acetylation by human NatB.

Authors:  Sunbin Deng; Buyan Pan; Leah Gottlieb; E James Petersson; Ronen Marmorstein
Journal:  Elife       Date:  2020-09-04       Impact factor: 8.140

Review 9.  Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease.

Authors:  Xian-Si Zeng; Wen-Shuo Geng; Jin-Jing Jia; Lei Chen; Peng-Peng Zhang
Journal:  Front Aging Neurosci       Date:  2018-04-17       Impact factor: 5.750

10.  Differential effects of Cu2+ and Fe3+ ions on in vitro amyloid formation of biologically-relevant α-synuclein variants.

Authors:  Emma Lorentzon; Ranjeet Kumar; Istvan Horvath; Pernilla Wittung-Stafshede
Journal:  Biometals       Date:  2020-03-13       Impact factor: 2.949

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.